Pluristem Therapeutics to Present Its Clinical Path at the International Society for Cellular Therapy (ISCT) 15th Annual Meeting
NEW YORK, Apr 28, 2009 (BUSINESS WIRE) -- Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today that Dr. Frida Grynspan, Pluristem's Vice President Research and Development, will present at the International Society for Cellular Therapy (ISCT), on "The pre-clinical path leading to the first-in-man clinical trial using PLX-PAD for the treatment of critical limb ischemia." This is the ISCT 15th Annual Meeting and it will be held on May 3-6, 2009, at the Sheraton San Diego Hotel and Marina.
"It is exciting to see Pluristem successfully completing the path from a pre-clinical company to a company with its own Good Manufacturing Practice (GMP) facility, an approved Food and Drug Administration (FDA) application to begin Phase I clinical trials in the US and a strong scientific team," stated Zami Aberman, Chairman, President and CEO of Pluristem. "At the ISCT we will present the scientific path which led Pluristem to begin first-in-man clinical trials using our placental adherent stromal cells product."
About the International Society for Cellular Therapy (ISCT)
The ISCT is the global forum and resource for developing and supporting innovative cellular therapies through communication, education, and training, thus furthering clinical based investigation for the benefit of patients. |
